A clinical study to evaluate the efficacy of shodhana navana nasya and avapeedana nasya in manyastambha

A RANDOMIZED OPEN LABELLED COMPARATIVE CLINICAL STUDY TO EVALUATE THE EFFICACY OF SHODHANA NAVANA NASYA AND AVAPEEDANA NASYA IN MANYASTAMBHA - ROCCSA

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/04/024794

Enrollment

Registered

2020-04-22

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M488- Other specified spondylopathies

Interventions

Intervention1: Shodhana navana nasya: Maha bringaraja taila 8 bindu in each nostrils for 7days Control Intervention1: Avapeedana nasya: Guda ardraka nasya 8 bindu in each nostrils for 7days

Eligibility

Inclusion criteria

Inclusion criteria: 1 Subjects with clinical signs and symptoms of manyastambha. 2 Age between 21-50 years old. 3 Subjects of either gender irrespective of religion and socio economic status. 4 Subjects fit for nasya

Exclusion criteria

Exclusion criteria: 1 Pregnant and lactating women. 2 Subjects with congenital deformity, traumatic injury, cervical stenosis and myelopathy, infections of bone and gross bony deformity and epistaxis. 3 Other systemic disorders which interfere in the line of treatment like uncontrolled diabetes, uncontrolled hypertension and cardio vascular disease.

Design outcomes

Primary

Measure	Time frame
There is no significant difference in the outcome of both shodhana navana nasya and avapeedana nasya.Timepoint: 7th day 14th day	—

Secondary

Measure	Time frame
Shodhana navana nasya is better than avapeedana nasyaTimepoint: 7th day 14th day	—

Countries

India

Contacts

Public ContactDr Haripriya Vasudev

SRI SRI COLLEGE OF AYURVEDIC SCIENCE AND RESEARCH

drmadhushreehs@rediffmail.com8095488376

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026